Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Open
Slide the cover down until you hear a click. The dose counter counts down by 1, and you’re ready to take one dose of your medicine
TRELEGY Ellipta: Not all COPD treatments are the same
TRELEGY Ellipta was intentionally designed to provide your COPD patients with sustained efficacy from today, so they can expect more from tomorrow.1-3
*Note: Villanterol and Fluticasone Furoate are not licensed as monotherapy in COPD.
Designed for sustained lung function improvement over 24 hours, from just one dose
TRELEGY Ellipta delivered sustained 24-hour efficacy on lung function from Day 1 to Week 244, and overall, a superior lung function improvement vs. budesonide/formoterol.2
Adapted from Lipson et al. 20174
First doses of TRELEGY Ellipta and budesonide/formoterol given at 0h; second dose of budesonide/formoterol given ~12h later
*MCID: Minimal clinically important difference. Patients with COPD have been shown to perceive an improvement of ≥100 mL
in trough FEV1 as beneficial5
The art of drug design
David Allen, Senior Vice President, Medicine Design, GSK Respiratory R&D, explains how the molecules of TRELEGY Ellipta were designed to provide a long duration of action for patients with COPD.1–3,6–8
Poor inhaler technique could be a reason why a patient's COPD symptoms are poorly controlled.9 With the Ellipta inhaler, significantly fewer patients made a critical error* compared with other commonly used COPD inhalers:10
4.6x fewer patients
made a critical error* with Ellipta vs. MDI
(Ellipta 13%; MDI 60%, p<0.001)10
Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)10
Adapted from van der Palen et al. 201610
*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
**This study assessed critical errors in the most common type of MDI (metered–dose inhaler) where shaking prior to use is required. The most common critical error with an MDI was poor actuation and inhalation coordination10
8.8x fewer patients
made a critical error* with Ellipta vs. Diskus
(Ellipta 5%; Diskus 44%, p<0.001)10
Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)10
Adapted from van der Palen et al. 201610
*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
5.5x fewer patients
made a critical error* with Ellipta vs. Turbuhaler
(Ellipta 8%; Turbuhaler 44%, p<0.001)10
Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)10
Adapted from van der Palen et al. 201610
*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
3.4x fewer patients
made a critical error* with Ellipta vs. Handihaler
(Ellipta 14%; Handihaler 48%, p<0.001)10
Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)10
Adapted from van der Palen et al. 201610
*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
3.5x fewer patients
made a critical error* with Ellipta vs. Breezhaler
(Ellipta 13%; Breezhaler 46%, p<0.001)10
Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)10
Adapted from van der Palen et al. 201610
*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
Ellipta inhaler: Designed for simplicity
Key steps to use TRELEGY Ellipta inhaler11
Get started with Trelegy Ellipta
Footnotes
FEV1, forced expiratory volume in one second; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; MDI, metered-dose inhaler; OD, once daily; QoL, quality of life
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA1
References
- TRELEGY Ellipta SmPC, 2022. Available at www.medicines.ie. Accessed February 2023.
- Lipson DA et al. Am J Crit Care Med 2017; 196:438–446.
- Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
- Lipson DA et al. Poster presented at ATS 2017; Poster 372 (A3605).
- Jones PW et al. Am J Respir Crit Care Med 2014; 189:250–255.
- Kempsford R et al. Pulm Pharmacol Ther 2013; 26:256–264.
- Biggadike K et al. J Med Chem 2008; 51:3349–3352.
- Lainé DI et al. J Med Chem 2009; 52:2493–2505.
- Riley JH et al. Int J Chron Obstruct Pulm Dis 2016; 11:1873–1880.
- Van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
- TRELEGY Ellipta Patient Information Leaflet, 2022, available at https://www.medicines.ie/medicines/trelegy-ellipta-34025/patient-info
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Trelegy is a registered trademark of the GlaxoSmithKline group of companies.
TRELEGY Ellipta was developed in collaboration with
Last Updated: February 2023 PM-IE-FVU-WCNT-220016
